18F-FDG accumulation in atherosclerotic plaques: immunohistochemical and PET imaging study

M Ogawa, S Ishino, T Mukai, D Asano… - Journal of Nuclear …, 2004 - Soc Nuclear Med
The rupture of atherosclerotic plaques and the subsequent formation of thrombi are the
main factors responsible for myocardial and cerebral infarctions. Thus, the detection of …

Drug‐like properties in macrocycles above MW 1000: backbone rigidity versus side‐chain lipophilicity

…, J Schwochert, CR Pye, D Asano… - Angewandte Chemie …, 2020 - Wiley Online Library
Large macrocyclic peptides can achieve surprisingly high membrane permeability, although
the properties that govern permeability in this chemical space are only beginning to come …

Lectin-like oxidized LDL receptor-1 (LOX-1) expression is associated with atherosclerotic plaque instability—analysis in hypercholesterolemic rabbits

S Ishino, T Mukai, N Kume, D Asano, M Ogawa, Y Kuge… - Atherosclerosis, 2007 - Elsevier
Lectin-like oxidized LDL receptor-1 (LOX-1), a cell-surface receptor for oxidized LDL (Ox-LDL),
has been implicated in vascular cell dysfunction related to atherosclerotic plaque …

Therapeutic effects of a 186Re-complex–conjugated bisphosphonate for the palliation of metastatic bone pain in an animal model

K Ogawa, T Mukai, D Asano… - Journal of Nuclear …, 2007 - Soc Nuclear Med
Previously, based on the concept of bifunctional radiopharmaceuticals, we developed a
highly stable 186 Re-mercaptoacetylglycylglycylglycine (MAG3) complex–conjugated …

Discovery of DS-1971a, a Potent, Selective NaV1.7 Inhibitor

…, R Koishi, C Fujiwara, D Asano… - Journal of Medicinal …, 2020 - ACS Publications
A highly potent, selective Na V 1.7 inhibitor, DS-1971a, has been discovered. Exploration of
the left-hand phenyl ring of sulfonamide derivatives (I and II) led to the discovery of novel …

Discovery of 1-[2-(1-methyl-1H-pyrazol-5-yl)-[1, 2, 4] triazolo [1, 5-a] pyridin-6-yl]-3-(pyridin-4-ylmethyl) urea as a potent NAMPT (nicotinamide …

…, K Terayama, M Yokoyama, J Tanaka, D Asano… - Bioorganic & Medicinal …, 2021 - Elsevier
Nicotinamide phosphoribosyltransferase (NAMPT) catalyzes the rate-limiting step of the
NAD + salvage pathway. Since NAD + plays a pivotal role in many biological processes …

[HTML][HTML] Oral Absorption of Middle-to-Large Molecules and Its Improvement, with a Focus on New Modality Drugs

D Asano, H Takakusa, D Nakai - Pharmaceutics, 2023 - mdpi.com
To meet unmet medical needs, middle-to-large molecules, including peptides and
oligonucleotides, have emerged as new therapeutic modalities. Owing to their middle-to-large …

Discovery of DS68702229 as a potent, orally available NAMPT (nicotinamide phosphoribosyltransferase) activator

…, M Yokoyama, J Tanaka, D Asano… - Chemical and …, 2021 - jstage.jst.go.jp
Nicotinamide phosphoribosyltransferase (NAMPT) catalyzes the rate-limiting step of the
nicotinamide adenine dinucleotide (NAD+) salvage pathway. Because NAD+ plays a pivotal …

[HTML][HTML] Renadirsen, a Novel 2′OMeRNA/ENA® Chimera Antisense Oligonucleotide, Induces Robust Exon 45 Skipping for Dystrophin In Vivo

…, N Takagi, H Nagase, N Watanabe, D Asano… - Current Issues in …, 2021 - mdpi.com
Duchenne muscular dystrophy (DMD) is a progressive muscle-wasting disease caused by
out-of-frame or nonsense mutation in the dystrophin gene. It begins with a loss of ambulation …

Chemical design of a radiolabeled gelatinase inhibitor peptide for the imaging of gelatinase activity in tumors

H Hanaoka, T Mukai, S Habashita, D Asano… - Nuclear medicine and …, 2007 - Elsevier
Since elevated levels of gelatinases [matrix metalloproteinase (MMP)-2 and MMP-9] are
associated with a poor prognosis in cancer patients, these enzymes are potential targets for …